ABSTRACT The Academy of Medicine (AMS) and the Ministry of Health (MOH) have developed the clinical practice guidelines on Attention Deficit Hyperactivity Disorder (ADHD) to provide doctors and patients in Singapore with evidencebased treatment for ADHD. This article reproduces the introduction and executive summary (with recommendations from the guidelines) from the MOH clinical practice guidelines on ADHD, for the information of SMJ readers. Chapters and page numbers mentioned in the reproduced extract refer to the full text of the guidelines, which are available from the Ministry of Health website: http://www.moh.gov.sg/content/moh_web/healthprofessionalsportal/doctors/guidelines/ cpg_medical.html.The recommendations should be used with reference to the full text of the guidelines. Following this article are multiple choice questions based on the full text of the guidelines.
Background information
Attention deficit hyperactivity disorder (ADHD) is a neuro-developmental disorder, characterised by the presence of early-onset persistent, pervasive and impairing hyperactiveimpulsive and/or inattentive symptoms. The worldwide pooled prevalence was about 5.29%. While there has been no epidemiological study on the prevalence of this condition among children in Singapore, a local study reported the prevalence of externalising problems to be 4.9% among Singaporean primary school children. While ADHD symptoms decline with age, a meta-analysis reported that a significant proportion might have residual symptoms in adulthood. ADHD has been reported to be associated with negative outcomes, including poor academic achievement, reduced self-esteem and higher smoking rate. This condition is often picked up when the child is young, and children with ADHD are often treated by child psychiatrists and paediatricians.
Objectives and scope of guideline
These guidelines are not meant to be viewed as a protocol, but rather, to provide a framework to:
• Approach the assessment process, with the goals of arriving at a diagnosis and planning treatment.
• Inform the practitioner about the level of evidence for medication available in Singapore, to aid the decision about medication use.
• Inform about the evidence for non-pharmacological treatment approaches to help professionals plan treatment and discuss these with parents.
Target group
The target group of these guidelines are professionals who come into contact with children and adolescents below the age of 18 who have attention deficit hyperactivity disorder (ADHD). The information is intended to help professionals plan the treatment for such children and adolescents. Professionals should exercise caution when extrapolating the evidence beyond this stated age group.
Guideline development
These guidelines were produced by a multi-disciplinary workgroup appointed by the Academy of Medicine, Singapore.
The workgroup comprised psychiatrists, paediatricians, educational psychologists, a medical social worker, a pharmacist, an advanced practice nurse and a parent representative. 
Review of guidelines

C
The clinician should assess a child diagnosed with attention deficit hyperactivity disorder for co-morbid conditions (pg 13). Grade C, Level 2 + C If there is a suspected learning disorder, appropriate p s y c h o -e d u c a t i o n a l o r s p e e c h a n d l a n g u a g e assessments should be sought from the appropriate specialists (pg 14). 
